[PDF][PDF] Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma
M Pashenkov, G Goëss, C Wagner… - Journal of Clinical …, 2006 - researchgate.net
M Pashenkov, G Goëss, C Wagner, M Hörmann, T Jandl, A Moser, CM Britten, J Smolle…
Journal of Clinical Oncology, 2006•researchgate.netPurpose The recent identification of toll-like receptors (TLRs) and respective ligands allows
the evaluation of novel dendritic cell (DC)–activating strategies. Stimulation of TLR9 directly
activates human plasmacytoid DCs (PDCs) and indirectly induces potent innate immune
responses in preclinical tumor models. We performed an open-label, multicenter, single-
arm, phase II pilot trial with a TLR9-stimulating oligodeoxynucleotide in melanoma patients.
the evaluation of novel dendritic cell (DC)–activating strategies. Stimulation of TLR9 directly
activates human plasmacytoid DCs (PDCs) and indirectly induces potent innate immune
responses in preclinical tumor models. We performed an open-label, multicenter, single-
arm, phase II pilot trial with a TLR9-stimulating oligodeoxynucleotide in melanoma patients.
Purpose
The recent identification of toll-like receptors (TLRs) and respective ligands allows the evaluation of novel dendritic cell (DC)–activating strategies. Stimulation of TLR9 directly activates human plasmacytoid DCs (PDCs) and indirectly induces potent innate immune responses in preclinical tumor models. We performed an open-label, multicenter, single-arm, phase II pilot trial with a TLR9-stimulating oligodeoxynucleotide in melanoma patients.
researchgate.net